Fairmont Hotel Vancouver Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2013
Here are the related meetings in 2019:
Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit (C2)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Cancer Immunology and Immunotherapy (J4)
Organizer(s) Glenn Dranoff, Carl H. June and Suzanne L. Topalian
January 27—February 1, 2013
Fairmont Hotel Vancouver • Vancouver, British Columbia Canada
Abstract Deadline: Sep 25, 2012
Late Abstract Deadline: Oct 25, 2012
Scholarship Deadline: Sep 25, 2012
Early Registration Deadline: Nov 27, 2012
Sponsored by Bayer USA Foundation and Bristol-Myers Squibb Company. Supported by an educational donation provided by Amgen.
Joint Meeting:
Antibodies as Drugs (J3)
Summary of Meeting:
The recent FDA approvals of Provenge® as the first therapeutic cancer vaccine and Ipilimumab® as the first monoclonal antibody that blocks negative immune regulation are landmark achievements that highlight substantive progress in cancer immunology. These novel treatments derive from the cumulative insights of basic and translational scientists into the mechanisms of protective tumor immunity in cancer patients. Advances in genetic, cellular and biochemical technologies have dramatically increased our understanding of the pathways through which the host responds to cancer. Tumor-host interactions in the microenvironment are increasingly recognized to play a critical role in determining disease inhibition or promotion. This Keystone Symposia meeting will bring together leading cancer immunologists to discuss their most recent insights into immune recognition, regulation, tumor escape and therapeutic manipulation. Emerging areas of cancer metabolism and material science engineering that relate to cancer immunology will be highlighted. The integration of basic and clinical aspects of tumor immunity in this meeting should stimulate interest from a wide array of investigators and students. The concurrent meeting on Antibodies as Drugs will underscore the increasing connections between these fields, and potentially accelerate the development of new cancer immunotherapies.
View Scholarships/Awards
The recent FDA approvals of Provenge® as the first therapeutic cancer vaccine and Ipilimumab® as the first monoclonal antibody that blocks negative immune regulation are landmark achievements that highlight substantive progress in cancer immunology. These novel treatments derive from the cumulative insights of basic and translational scientists into the mechanisms of protective tumor immunity in cancer patients. Advances in genetic, cellular and biochemical technologies have dramatically increased our understanding of the pathways through which the host responds to cancer. Tumor-host interactions in the microenvironment are increasingly recognized to play a critical role in determining disease inhibition or promotion. This Keystone Symposia meeting will bring together leading cancer immunologists to discuss their most recent insights into immune recognition, regulation, tumor escape and therapeutic manipulation. Emerging areas of cancer metabolism and material science engineering that relate to cancer immunology will be highlighted. The integration of basic and clinical aspects of tumor immunity in this meeting should stimulate interest from a wide array of investigators and students. The concurrent meeting on Antibodies as Drugs will underscore the increasing connections between these fields, and potentially accelerate the development of new cancer immunotherapies.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
SUNDAY, JANUARY 27
MONDAY, JANUARY 28
TUESDAY, JANUARY 29
WEDNESDAY, JANUARY 30
THURSDAY, JANUARY 31
FRIDAY, FEBRUARY 1
Conference Program Print | View meeting in 12 hr (am/pm) time
SUNDAY, JANUARY 27
19:15—20:30
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.
*
Glenn Dranoff,
Novartis Institutes for BioMedical Research, USA
James P. Allison,
University of Texas MD Anderson Cancer Center, USA
Checkpoint Blockade
Checkpoint Blockade
19:15—20:30
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.
*
Paul Carter,
Genentech, Inc., USA
*
Andreas G. Plückthun,
University of Zürich, Switzerland
Jeffrey V. Ravetch,
Rockefeller University, USA
Solving the Antibody Paradox
Solving the Antibody Paradox
08:00—11:00
Tumor Targeting - From Understanding Mechanisms to New Targeting Agents (Joint)
Meeting has ended...abstracts no longer viewable online.
*
Dario Neri,
ETH Zürich, Switzerland
Karl Dane Wittrup,
Massachusetts Institute of Technology, USA
Synergistic Antibody and Cytokine Effects in Cancer Immunotherapy
Synergistic Antibody and Cytokine Effects in Cancer Immunotherapy
Kerry A. Chester,
University College London Cancer Institute, UK
Antibody-Targeted Nanoparticles for Cancer Treatment
Antibody-Targeted Nanoparticles for Cancer Treatment
Erkki Ruoslahti,
Sanford-Burnham Medical Research Institute, USA
Increasing Extravasation with Peptides
Increasing Extravasation with Peptides
Anna M. Wu,
University of California, Los Angeles, USA
Engineered Antibodies for Molecular Imaging of Cancer
Engineered Antibodies for Molecular Imaging of Cancer
Henry B. Lowman,
CytomX, USA
Short Talk: Probody™ Therapeutics: A New Class of Proteolytically Activated Antibodies
Short Talk: Probody™ Therapeutics: A New Class of Proteolytically Activated Antibodies
14:30—16:30
Workshop 1: Emerging Antibody Generation Methods
*
James D. Marks,
University of California, San Francisco, USA
Filippa Fleetwood,
Royal Institute of Technology, Sweden
Surface Display of a Single-Domain Antibody Library on Gram-Positive Bacteria
Surface Display of a Single-Domain Antibody Library on Gram-Positive Bacteria
Christian Kunz,
MorphoSys AG, Germany
The Role of HuCAL in the Discovery of Lead Antibodies with a Unique MoA
The Role of HuCAL in the Discovery of Lead Antibodies with a Unique MoA
Audrey D. McConnell,
AnaptysBio, Inc., USA
High Affinity Humanized Antibodies without Making Hybridomas; Immunization Paired with Mammalian Cell Display and in vitro Somatic Hypermutation
High Affinity Humanized Antibodies without Making Hybridomas; Immunization Paired with Mammalian Cell Display and in vitro Somatic Hypermutation
Amandeep K. Gakhal,
Sutro Biopharma, USA
A New Method for Direct Selection of Synthetic Antibody Fragments on Cell Surface Targets from a Phage-Displayed Library
A New Method for Direct Selection of Synthetic Antibody Fragments on Cell Surface Targets from a Phage-Displayed Library
Hiroshi Hamana,
University of Toyama, Japan
Rabbit ISSAC (Rabbit Immunospot Array Assay on a Chip) Allows for the Rapid Generation of Rabbit Monoclonal Antibodies with High Affinity
Rabbit ISSAC (Rabbit Immunospot Array Assay on a Chip) Allows for the Rapid Generation of Rabbit Monoclonal Antibodies with High Affinity
Kai Zhu,
Schrodinger Inc., USA
Ab initio Structure Prediction of the Antibody Hypervariable H3 Loop
Ab initio Structure Prediction of the Antibody Hypervariable H3 Loop
17:00—19:00
Tumor Microenvironment
Meeting has ended...abstracts no longer viewable online.
*
James P. Allison,
University of Texas MD Anderson Cancer Center, USA
Wolf-Hervé Fridman,
Cordeliers Research Centre, France
The Immune Microenvironment of Primary and Metastatic Human Tumors
The Immune Microenvironment of Primary and Metastatic Human Tumors
Robert D. Schreiber,
Washington University School of Medicine, USA
Cancer Immunoediting: Antigens, Mechanisms and Implications for Cancer Immunotherapy
Cancer Immunoediting: Antigens, Mechanisms and Implications for Cancer Immunotherapy
Nikhil S. Joshi,
Yale University School of Medicine, USA
Short Talk: Effector Regulatory T Cell Differentiation during Autochthonous Mouse Lung Adenocarcinoma Development
Short Talk: Effector Regulatory T Cell Differentiation during Autochthonous Mouse Lung Adenocarcinoma Development
Drew M. Pardoll,
Johns Hopkins University School of Medicine, USA
Inflammation and Cancer
Inflammation and Cancer
17:00—19:00
Payloaded Antibodies for Cancer Treatment
Meeting has ended...abstracts no longer viewable online.
*
Peter D. Senter,
Seattle Genetics Inc., USA
Empowered Antibodies for Cancer Therapy
Empowered Antibodies for Cancer Therapy
Dario Neri,
ETH Zürich, Switzerland
Armed Antibodies for Vascular Targeting
Armed Antibodies for Vascular Targeting
Paul G. Polakis,
Genentech, Inc., USA
Antibody Drug Conjugates for the Treatment of Cancer
Antibody Drug Conjugates for the Treatment of Cancer
Brian J. Agnew,
Thermo Fisher Scientific, USA
Short Talk: Site-Selective Antibody Labeling without Engineering: Answering Unmet Needs in Antibody Payload Conjugation
Short Talk: Site-Selective Antibody Labeling without Engineering: Answering Unmet Needs in Antibody Payload Conjugation
08:00—11:15
Engineering and Immunotherapy
Meeting has ended...abstracts no longer viewable online.
*
Suzanne L. Topalian,
Johns Hopkins University School of Medicine, USA
Darrell J. Irvine,
Massachusetts Institute of Technology, USA
Interfacing Nanoparticle Drug Carriers with Lymphocytes to Enhance Cellular Immunotherapy
Interfacing Nanoparticle Drug Carriers with Lymphocytes to Enhance Cellular Immunotherapy
Hollie J. Jackson,
Memorial Sloan Ketter Cancer Center, USA
Short Talk: Expansion and Modification of Umbilical Cord Blood T Cells with a Chimeric Antigen Receptor and IL-12
Short Talk: Expansion and Modification of Umbilical Cord Blood T Cells with a Chimeric Antigen Receptor and IL-12
Sheena N. Smith,
University of Zurich, Switzerland
Short Talk: Engineering Designer T Cell Receptors through the Use of Single-Chain T Cell Receptor Scaffolds
Short Talk: Engineering Designer T Cell Receptors through the Use of Single-Chain T Cell Receptor Scaffolds
Laurence J. N. Cooper,
ZIOPHARM Oncology, Inc., USA
Sleeping Beauty Transposition for Engineered T Cells
Sleeping Beauty Transposition for Engineered T Cells
08:00—11:15
Antibodies in Infectious Diseases
Meeting has ended...abstracts no longer viewable online.
Antonio Lanzavecchia,
Institute for Research in Biomedicine, Switzerland
Human Antibodies to Infectious Disease Targets
Human Antibodies to Infectious Disease Targets
*
Dennis R. Burton,
The Scripps Research Institute, USA
Broadly Neutralizing Antibodies to Identify Vaccine Targets on HIV
Broadly Neutralizing Antibodies to Identify Vaccine Targets on HIV
Gary J. Nabel,
Sanofi, USA
Broadly Neutralizing Antibodies to HIV: A Model for Prevention and Treatment of an Infectious Disease
Broadly Neutralizing Antibodies to HIV: A Model for Prevention and Treatment of an Infectious Disease
George Georgiou,
University of Texas at Austin, USA
Proteomic Deconvolution of the Human Serological IgG Repertoire in Vaccine Evaluation and Antibody Discovery
Proteomic Deconvolution of the Human Serological IgG Repertoire in Vaccine Evaluation and Antibody Discovery
17:00—19:00
Cancer Vaccines
Meeting has ended...abstracts no longer viewable online.
*
Carl H. June,
University of Pennsylvania, USA
Cornelia Liu Trimble,
Johns Hopkins University School of Medicine, USA
Tissue T Cells in HPV Disease
Tissue T Cells in HPV Disease
Cornelis J. M. Melief,
Leiden University Medical Center & ISA pharmaceuticals BV, Netherlands
Chemo-Immunotherapy of High Risk HPV Infections
Chemo-Immunotherapy of High Risk HPV Infections
Marieke Griffioen,
Leiden University Medical Center, Netherlands
Short Talk: Intercellular Transfer of Natural HLA Class II Ligands Is Mediated by Full Length Proteins with Abundant Cellular Expression that Are Sequestered and Secreted into Microvesicles
Short Talk: Intercellular Transfer of Natural HLA Class II Ligands Is Mediated by Full Length Proteins with Abundant Cellular Expression that Are Sequestered and Secreted into Microvesicles
David H. Kirn,
Jennerex, USA
Targeted Oncolytic and Immunotherapeutic Viruses: Emerging Multi-Mechanistic Biologics for Cancer
Targeted Oncolytic and Immunotherapeutic Viruses: Emerging Multi-Mechanistic Biologics for Cancer
17:00—19:00
New Technologies for Generating Proteins with Novel Functions
Meeting has ended...abstracts no longer viewable online.
*
Andreas G. Plückthun,
University of Zürich, Switzerland
Andrew D. Ellington,
University of Texas at Austin, USA
Rational Engineering of Antibodies for Affinity and Stability
Rational Engineering of Antibodies for Affinity and Stability
Julia Shifman,
Hebrew University of Jerusalem, Israel
Computational Design of Protein-Protein Interactions
Computational Design of Protein-Protein Interactions
Romain Rouet,
University of California, Berkeley, USA
Short Talk: Stability Engineering of Human Antibody Therapeutics
Short Talk: Stability Engineering of Human Antibody Therapeutics
08:00—11:15
Adoptive Cellular Therapy
Meeting has ended...abstracts no longer viewable online.
*
Laurence Zitvogel,
Institut Gustave Roussy, France
Stanley R. Riddell,
Fred Hutchinson Cancer Research Center, University of Washington, USA
Chimeric Antigen Receptor Design and T Cell Subsets in Adoptive Therapy
Chimeric Antigen Receptor Design and T Cell Subsets in Adoptive Therapy
Kazuhiro Kakimi,
University of Tokyo Hospital, Japan
Short Talk: Autologous gammadelta T Cell Transfer Therapy for the Treatment of Solid Cancer
Short Talk: Autologous gammadelta T Cell Transfer Therapy for the Treatment of Solid Cancer
Nicholas P. Restifo,
NCI, National Institutes of Health, USA
Memory T Cells Precede Effector Cells: Why it Matters for ACT
Memory T Cells Precede Effector Cells: Why it Matters for ACT
Catherine M. Bollard,
Children’s National Health System, USA
T Cell Therapies for EBV+ Lymphomas – Where Have We Come From and Where Are We Going?
T Cell Therapies for EBV+ Lymphomas – Where Have We Come From and Where Are We Going?
Yanxia Guo,
Bristol Myers Squibb, USA
Short Talk: Retinoic Acid-Rich Microenvironment Provides Clonal Survival Cues for Tumor and Bacteria-Specific CD8+ T Cells
Short Talk: Retinoic Acid-Rich Microenvironment Provides Clonal Survival Cues for Tumor and Bacteria-Specific CD8+ T Cells
Robert S. Negrin,
Stanford University, USA
Immunobiology of Allogeneic Hematopoietic Cell Transplantation
Immunobiology of Allogeneic Hematopoietic Cell Transplantation
08:00—11:00
Modulating the Activity of Growth Factor Receptors
Meeting has ended...abstracts no longer viewable online.
*
Karl Dane Wittrup,
Massachusetts Institute of Technology, USA
Ermanno Gherardi,
University of Pavia, Italy
Structure/Function and Therapeutic Targeting of HGF/SF and MET
Structure/Function and Therapeutic Targeting of HGF/SF and MET
Andreas G. Plückthun,
University of Zürich, Switzerland
Engineering Receptor Ligands for Powerful Cellular Responses
Engineering Receptor Ligands for Powerful Cellular Responses
Yosef Yarden,
Weizmann Institute of Science, Israel
Antibodies to EGFR Family as Drugs
Antibodies to EGFR Family as Drugs
Carlos F. Barbas III,
The Scripps Research Institute, USA
Multifunctional and Multi-Specific Antibodies: Single-Protein Combination Therapeutics
Multifunctional and Multi-Specific Antibodies: Single-Protein Combination Therapeutics
Klaus Koefoed,
Symphogen A/S, Denmark
Short Talk: In vitro Comparison of EGFR/Her3 Targeting Antibody Mixtures and Bispecific MEHD7945A Analogue Shows More Efficacious Inhibition by Mixtures, Even Under Conditions Mimicking Cancer Resistance
Short Talk: In vitro Comparison of EGFR/Her3 Targeting Antibody Mixtures and Bispecific MEHD7945A Analogue Shows More Efficacious Inhibition by Mixtures, Even Under Conditions Mimicking Cancer Resistance
14:30—16:30
Workshop: Advances in Cancer Immunology
*
Wolf-Hervé Fridman,
Cordeliers Research Centre, France
Sally Amos,
BC Cancer Agency, Canada
Human Bilateral Breast Cancer: A Unique Opportunity to Examine Behaviors of Tumor-Infiltrating Lymphocytes
Human Bilateral Breast Cancer: A Unique Opportunity to Examine Behaviors of Tumor-Infiltrating Lymphocytes
Sarah Q. Crome,
University Health Network, Canada
Regulatory Natural Killer Cells Inhibit Anti-Tumour T Cells
Regulatory Natural Killer Cells Inhibit Anti-Tumour T Cells
Connie Duong,
Peter MacCallum Cancer Centre, Australia
Generating Stronger T Cells for Adoptive Immunotherapy
Generating Stronger T Cells for Adoptive Immunotherapy
Daniel T. Fisher,
Roswell Park Cancer Institute, USA
Thermal Activation of IL-6 Trans-Signaling Licenses Mouse and Human Tumor Microvascular Gateways for Trafficking of Cytotoxic T Cells
Thermal Activation of IL-6 Trans-Signaling Licenses Mouse and Human Tumor Microvascular Gateways for Trafficking of Cytotoxic T Cells
Richard P. Junghans,
Roger Williams Hospital, USA
Phase I Trial Data in Prostate Cancer Suggest Critical Role for IL2 Adjunctive Co-Therapy for Successful Suppression of Solid Tumor with Designer T Cells
Phase I Trial Data in Prostate Cancer Suggest Critical Role for IL2 Adjunctive Co-Therapy for Successful Suppression of Solid Tumor with Designer T Cells
Brian Ruffell,
Oregon Health & Science University, USA
Macrophages Regulate Response to Chemotherapy in Mammary Carcinomas
Macrophages Regulate Response to Chemotherapy in Mammary Carcinomas
14:30—16:30
Workshop 2: Enhancing Effector Functions and Extending Half-Life
*
Henry B. Lowman,
CytomX, USA
Javier Chaparro-Riggers,
Rinat-Pfizer Inc., USA
Improving PK and Cholesterol Lowering by a pH-Sensitive Anti-PCSK9-Antibody
Improving PK and Cholesterol Lowering by a pH-Sensitive Anti-PCSK9-Antibody
Jonathan Sockolosky,
University of California, San Francisco, USA
Engineering FcRn-Mediated Recycling and Transcytosis in Recombinant Proteins by Short Terminal Peptide Extensions
Engineering FcRn-Mediated Recycling and Transcytosis in Recombinant Proteins by Short Terminal Peptide Extensions
Tomoyuki Igawa,
Chugai Pharmaceutical, Japan
Engineered Antibody Fc Variant with Selectively Enhanced FcgammaRIIb Binding Over Both FcgammaRIIaR131 and FcgammaRIIaH131
Engineered Antibody Fc Variant with Selectively Enhanced FcgammaRIIb Binding Over Both FcgammaRIIaR131 and FcgammaRIIaH131
Elizabeth L. Smith,
University of California, Berkeley, USA
Antibody Glycoengineering with Aldehyde Tag Technology
Antibody Glycoengineering with Aldehyde Tag Technology
Surjit B. Dixit,
Zymeworks Inc., Canada
AlbuCORE™ – Structure-Guided Engineering and Design of a Multi-Valent Albumin Scaffold
AlbuCORE™ – Structure-Guided Engineering and Design of a Multi-Valent Albumin Scaffold
17:00—19:00
Metabolism and Cancer
Meeting has ended...abstracts no longer viewable online.
*
Stanley R. Riddell,
Fred Hutchinson Cancer Research Center, University of Washington, USA
Laurence Zitvogel,
Institut Gustave Roussy, France
Role of Type 1 IFN and dsRNA Sensors in the T Cell-Dependent Efficacy of Chemotherapy
Role of Type 1 IFN and dsRNA Sensors in the T Cell-Dependent Efficacy of Chemotherapy
Courtney Crane,
University of Washington, USA
Short Talk: Tumor Derived Lactate Dehydrogenase Drives Innate Immune Cell Crosstalk in Patients
Short Talk: Tumor Derived Lactate Dehydrogenase Drives Innate Immune Cell Crosstalk in Patients
17:00—19:15
Bispecific and Multispecific Targeting Agents
Meeting has ended...abstracts no longer viewable online.
*
Paul Carter,
Genentech, Inc., USA
Kaspar Binz,
Molecular Partners, Switzerland
Exploiting Novel Therapeutic Mechanisms Using Multi-Specific DARPins
Exploiting Novel Therapeutic Mechanisms Using Multi-Specific DARPins
James D. Marks,
University of California, San Francisco, USA
Development and Mechanism of Action of mAb Combinations that Potently Neutralize Botlinum Neurotoxin
Development and Mechanism of Action of mAb Combinations that Potently Neutralize Botlinum Neurotoxin
Lutz Jermutus,
MedImmune LLC, UK
A Novel Multi-Mechanistic Monoclonal Antibody Format for Treating Pseudomonas aeruginosa Infections
A Novel Multi-Mechanistic Monoclonal Antibody Format for Treating Pseudomonas aeruginosa Infections
Janine Schuurman,
Genmab B.V., Netherlands
Short Talk: Efficient Generation of Stable Bispecific IgG1 by Controlled Fab-Arm Exchange
Short Talk: Efficient Generation of Stable Bispecific IgG1 by Controlled Fab-Arm Exchange
David Poon,
Zymeworks Inc., Canada
Short Talk: Azymetric™ Scaffold – Optimized Fc Heterodimer for Improved Purity and Stability in the Development of Bispecific Antibodies
Short Talk: Azymetric™ Scaffold – Optimized Fc Heterodimer for Improved Purity and Stability in the Development of Bispecific Antibodies
08:00—11:15
Immunomodulatory Antibody Therapies (Joint)
Meeting has ended...abstracts no longer viewable online.
*
George J. Weiner,
University of Iowa, USA
Suzanne L. Topalian,
Johns Hopkins University School of Medicine, USA
PD-1 Blockade in Cancer Therapy
PD-1 Blockade in Cancer Therapy
Li Wang,
Medical College of Wisconsin, USA
Short Talk: Targeting a Novel Immune Checkpoint Protein VISTA Alters Tumor Microenvironment and Synergizes with Cancer Vaccine to Eradicate Established Melanoma
Short Talk: Targeting a Novel Immune Checkpoint Protein VISTA Alters Tumor Microenvironment and Synergizes with Cancer Vaccine to Eradicate Established Melanoma
Nils Lonberg,
Bristol-Myers Squibb, USA
Development Hurdles for Immuno-Oncology Antibody Drugs
Development Hurdles for Immuno-Oncology Antibody Drugs
Johannes vom Berg,
University of Zürich, Switzerland
Short Talk: Local Interleukin-12 in Combination with Systemic Checkpoint Blockade Leads to T-Cell Dependent Rejection of Advanced Stage Glioma
Short Talk: Local Interleukin-12 in Combination with Systemic Checkpoint Blockade Leads to T-Cell Dependent Rejection of Advanced Stage Glioma
Patrick A. Baeuerle,
Amgen Research (Munich) GmbH, Germany
Immunotherapy with BiTE® Antibodies: Lessons Learned from Blinatumomab
Immunotherapy with BiTE® Antibodies: Lessons Learned from Blinatumomab
Bent Jakobsen,
Immunocore Ltd., UK
IMCgp100: A Bispecific TCR Anti-CD3 Fusion for the Treatment of Malignant Melanoma
IMCgp100: A Bispecific TCR Anti-CD3 Fusion for the Treatment of Malignant Melanoma
17:00—19:00
Anti-Cancer Antibodies
Meeting has ended...abstracts no longer viewable online.
*
Nils Lonberg,
Bristol-Myers Squibb, USA
George J. Weiner,
University of Iowa, USA
Therapeutic Mechanisms of Monoclonal Antibodies
Therapeutic Mechanisms of Monoclonal Antibodies
Timo K. van den Berg,
Sanquin Blood Supply, Netherlands
Short Talk: CD47-SIRPalpha Interactions Form a Barrier for Antibody-Mediated Tumor Cell Destruction by Phagocytes
Short Talk: CD47-SIRPalpha Interactions Form a Barrier for Antibody-Mediated Tumor Cell Destruction by Phagocytes
Ronald P. DeMatteo,
Memorial Sloan-Kettering Cancer Center, USA
Combined Immunologic and Molecular Therapy for Cancer
Combined Immunologic and Molecular Therapy for Cancer
Glenn Dranoff,
Novartis Institutes for BioMedical Research, USA
Therapy-Induced Antibody Responses
Therapy-Induced Antibody Responses
17:00—19:00
Challenges and New Opportunities with Antibody Drugs
Meeting has ended...abstracts no longer viewable online.
*
Kerry A. Chester,
University College London Cancer Institute, UK
Ryan J. Watts,
Denali Therapeutics Inc, USA
Engineering Bispecific Blood-Brain Barrier Crossing Antibodies
Engineering Bispecific Blood-Brain Barrier Crossing Antibodies
Sripad Ram,
University of Texas Southwestern Medical Center, USA
Short Talk: Multifocal Plane Microscopy Reveals Novel Intracellular Trafficking Pathways at the Blood-Brain Barrier with Implications to Antibody Delivery to the Brain
Short Talk: Multifocal Plane Microscopy Reveals Novel Intracellular Trafficking Pathways at the Blood-Brain Barrier with Implications to Antibody Delivery to the Brain
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors for generously supporting this meeting:
|
|
|
|
We gratefully acknowledge additional support for this conference from:
|
|
|
|
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
|
Cancer Immunity |
|
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Development, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org, Phone:+1 970-262-2676 |
